Medical device maker Boston Scientific's (NYSE:BSX) been one of health care's biggest success stories over the past year, with this standout stock climbing 89% over that time. However, its performance hasn't quite lived up to its investors' rewards. Its struggles with revenue as the cardiac rhythm management and stent industries have slowed since the recession, and the company's suffered falling sales in each of the last two years.

Boston Scientific's doing the best it can to turn around that ominous trend. It's managed to slow down revenue losses in its two largest divisions, cardiac rhythm management and interventional cardiology. Meanwhile, up-and-coming businesses such as neuromodulation have stepped up with much-needed revenue growth, although Boston's neurotech sales currently only provide less than a tenth of its overall revenue.

Earnings season's at hand for Boston Scientific, but what should you be watching for when the company reports its quarterly performance on April 29? In the video below, Motley Fool contributor Dan Carroll takes you through the three trends you need to keep an eye on at Boston and whether this company's performance can keep this surging stock on a roll through 2014.

Will Boston Scientific lead the next wave of health-care innovation?
Innovation from forward-thinking companies like Boston Scientific paves the way for huge profits in the health-care sector, and you can't afford to miss out on what could be the next game changer in the medical world. The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And the technology behind it is poised to set off one of the most remarkable health-care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential and its ability to make life-changing medical solutions never thought possible.  To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers